Dysfunctional HDL and atherosclerotic cardiovascular disease

Robert S. Rosenson(Icahn School of Medicine at Mount Sinai), H. Bryan Brewer(MedStar Washington Hospital Center), Benjamin J. Ansell(University of California, Los Angeles), Philip J. Barter(UNSW Sydney), M. John Chapman(Sorbonne Université), Jay W. Heinecke(University of Washington), Anatol Kontush(Inserm), Alan R. Tall(Columbia University), Nancy R. Webb(University of Kentucky)

Nature Reviews Cardiology

September 1, 2015

10.1038/nrcardio.2015.124

Cited by 790

Abstract

Related Papers

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

The HPS2-THRIVE Collaborative Group|New England Journal of Medicine|2014|1.7k

Cholesterol Efflux and Atheroprotection

Robert S. Rosenson, H. Bryan Brewer, W. Sean Davidson et al.|Circulation|2012|950

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

Ivan S. Yuhanna, Yan Zhu, Blair E. Cox et al.|Nature Medicine|2001|743

Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition.

Gerhard A. Coetzee, A F Strachan, D R van der Westhuyzen et al.|Journal of Biological Chemistry|1986|424

Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy

Sajoscha Sorrentino, Christian Besler, Lucia Rohrer et al.|Circulation|2009|404